CED requires fine catheters to be placed directly into the tumor. This approach allows for therapy to be placed directly in the tumor avoiding systemic toxicity and higher dosages.
Dr Bruce has worked for more than a decade in development of CED for malignant gliomas. His initial publications were in 2000 with a rat glioma model. In 2011, Bruce has authored three publications regarding CED with topotecan for malignant glioma.
Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model
Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors
Regression of Recurrent Malignant Gliomas with Convection-Enhanced Delivery of Topotecan
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump
In addition to
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
The NIH has piloted CED in the brainstem not only for DIPG but also for other issues. In 2007, the NIH published technical notes on two children that received CED therapy. One of these children had a DIPG and the other had Gaucher’s Disease.
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note.